Search Results

Astria Therapeutics, Inc. today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting in Washington, D.C. on February 23, 2024 at 3:15pm EST.

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting taking place in Washington, DC from February 23-26.

Intrommune Therapeutics, Inc. today announced data from The First Study To Evaluate Oral Mucosal Immunotherapy (OMIT) For The Treatment Of Food Allergy has been selected as a Late Breaking Poster Presentation at the 2024 American Academy of Allergy, Asthma & Immunology in Washington, DC.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper) is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held February 23-26 in Washington, D.C.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that it presented additional data on its phase 3 KONFIDENT trial for sebetralstat, including a more in-depth analysis of sebetralstat efficacy and safety at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC.

KalVista Pharmaceuticals, Inc. announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting that took place in Washington, DC.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

Kinaset Therapeutics today announced an upcoming oral presentation at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held on February 23-26, 2024.

Astria Therapeutics, Inc. today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

BioCryst Pharmaceuticals Inc. announced that new data on oral, once-daily ORLADEYO® for the prophylactic treatment of hereditary angioedema will be presented at the European Academy of Allergy and Clinical Immunology meeting in Valencia, Spain from May 31 to June 3, 2024.